Date: 04/01/2016
Whitman Walker Health’s Megan Coleman appeared on Good Morning Washington on Thursday, March 31, 2016 to talk about HIV Pre-Exposure Prophylaxis (PrEP)
Click HERE or on the photo to view the video.
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design
TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
